Form 8-K - Current report:
SEC Accession No. 0001558370-25-000105
Filing Date
2025-01-10
Accepted
2025-01-10 09:27:51
Documents
15
Period of Report
2025-01-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ymab-20250106x8k.htm   iXBRL 8-K 54382
2 EX-99.1 ymab-20250106xex99d1.htm EX-99.1 30960
3 GRAPHIC ymab-20250106xex99d1001.jpg GRAPHIC 5034
  Complete submission text file 0001558370-25-000105.txt   226159

Data Files

Seq Description Document Type Size
4 EX-101.SCH ymab-20250106.xsd EX-101.SCH 3413
5 EX-101.LAB ymab-20250106_lab.xml EX-101.LAB 15928
6 EX-101.PRE ymab-20250106_pre.xml EX-101.PRE 10320
17 EXTRACTED XBRL INSTANCE DOCUMENT ymab-20250106x8k_htm.xml XML 4797
Mailing Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169
Business Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169 212-847-9841
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

EIN.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38650 | Film No.: 25520824
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)